GrantPostedDiscretionary

Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)

National Institutes of Health
PA-25-253
Application Deadline
Sep 7, 2028
853 days left
Days Remaining
853
Until deadline
Award Ceiling
Total Program Funding

Grant Opportunity Analysis

The National Institutes of Health (NIH) is offering Exploratory Grants in Cancer Control through the R21 Clinical Trial Optional mechanism, aimed at advancing innovative research in cancer control. This funding opportunity encourages applications focused on behavioral modification, screening, and understanding the etiological factors of cancer, with the goal of developing novel methodologies and tools that can significantly impact population-based cancer research. Grants of up to $275,000 are available for projects lasting up to two years, with application deadlines beginning January 16, 2025, and continuing through 2028. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PA-25-253.html.

Eligible Applicants

Others
Additional Eligibility Information

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Grant Documents

2 Files
PA-25-253-Full-Announcement.html
HTML0 KBNov 13, 2024
AI Summary
No AI summary available for this file.
PA-25-253.html
HTML119 KBNov 13, 2024
AI Summary
The National Cancer Institute (NCI) under the Department of Health and Human Services is offering Exploratory Grants in Cancer Control through the R21 Clinical Trial Optional mechanism. This funding opportunity focuses on novel and high-risk research aimed at improving cancer control via behavioral modification, screening, and understanding cancer etiology. The goal is to develop innovative methodologies and tools that can significantly advance population-based cancer research, ultimately aiming to reduce cancer risk, incidence, and enhance survivor quality of life. Applications are welcomed from a range of eligible entities, including higher education institutions, nonprofits, and for-profit organizations. Each grant supports a maximum of $275,000 for a project duration of up to two years. Key deadlines for applications begin on January 16, 2025, with various submission cycles extending through 2028. The proposal review includes evaluations of significance, innovation, and scientific rigor, highlighting the importance of addressing gaps in cancer control research. This funding no longer requires extensive preliminary data, encouraging early-stage research. Key topics include behavioral interventions, healthcare delivery, epidemiology, and cancer surveillance, thus emphasizing the necessity of comprehensive strategies to reduce health disparities and improve patient outcomes in cancer care.

Related Grant Opportunities

Project Timeline

postedOriginal Opportunity PostedNov 12, 2024
deadlineApplication DeadlineSep 7, 2028
expiryArchive DateOct 13, 2028

Funding Details

No cost sharing required

Agency & Classification

Agency
National Institutes of Health(HHS-NIH11)
Funding Category
Health
Funding Instrument
Grant

Grantor Contact

CFDA Numbers

93.399

Official Sources